S. SEZGİN GÖKSU Et Al. , "Cetuximab-induced rash is associated with overall survival in patients with recurrent/metastatic squamous cell carcinoma of head and neck," Cancer Chemotherapy and Pharmacology , vol.88, no.5, pp.805-812, 2021
SEZGİN GÖKSU, S. Et Al. 2021. Cetuximab-induced rash is associated with overall survival in patients with recurrent/metastatic squamous cell carcinoma of head and neck. Cancer Chemotherapy and Pharmacology , vol.88, no.5 , 805-812.
SEZGİN GÖKSU, S., TATLI, A. M., Geredeli, Ç., Atcı, M., Besen, A. A., Mertsoylu, H., ... Uysal, M.(2021). Cetuximab-induced rash is associated with overall survival in patients with recurrent/metastatic squamous cell carcinoma of head and neck. Cancer Chemotherapy and Pharmacology , vol.88, no.5, 805-812.
SEZGİN GÖKSU, SEMA Et Al. "Cetuximab-induced rash is associated with overall survival in patients with recurrent/metastatic squamous cell carcinoma of head and neck," Cancer Chemotherapy and Pharmacology , vol.88, no.5, 805-812, 2021
SEZGİN GÖKSU, SEMA S. Et Al. "Cetuximab-induced rash is associated with overall survival in patients with recurrent/metastatic squamous cell carcinoma of head and neck." Cancer Chemotherapy and Pharmacology , vol.88, no.5, pp.805-812, 2021
SEZGİN GÖKSU, S. Et Al. (2021) . "Cetuximab-induced rash is associated with overall survival in patients with recurrent/metastatic squamous cell carcinoma of head and neck." Cancer Chemotherapy and Pharmacology , vol.88, no.5, pp.805-812.
@article{article, author={SEMA SEZGİN GÖKSU Et Al. }, title={Cetuximab-induced rash is associated with overall survival in patients with recurrent/metastatic squamous cell carcinoma of head and neck}, journal={Cancer Chemotherapy and Pharmacology}, year=2021, pages={805-812} }